ARES Technology
AI powered DNA Testing
Ares Genetics’ combines Next Generation Sequencing (NGS) with ARESdb, the world‘s most comprehensive database on the genetics of antibiotic resistance.
ARESdb
ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally.
ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with up to more than 98%.
Global DB
ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR.
>150 Digital AMR Panels
ARESdb is the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels.
Broad Pathogen Coverage
ARESdb combines deep whole-genome sequencing data with antibiotic resistance profiles and is continuously expanded.
ARES Platform
Our proprietary digital health platform combines a NGS-based Universal Pathogenome Assay (ARESupa) with a cloud based decision support & reporting system (AREScds) that is sustainably keeping pace with rapidly evolving AMR based on an Artificial Intelligence powered in-vitro diagnostics (IVD) Reference Database (ARESdb).
ARESdb
Most comprehensive, global and continuously updated proprietary knowledgebase on genetic antibiotic resistance marker and their diagnostic relevance.
Powered by AI
Semi-automated resistance marker discovery, prioritization and validation engine. AI-informed database expansion from structured and unstructured AMR data to diagnostics markers based on expert-defined evidence levels.
ARESupa
Universal Pathogenome Assay (UPA) for any patient sample.
AREScds
Secure & HIPAA compliant cloud-based Clinical Decision Support system (CDS) linking AMR markers to treatment response.
Applications
A Universal Test for Any Patient
At Ares Genetics, we are developing a rapid, DNA-based test for universal pathogen diagnostics and drug response prediction.
Advancing Diagnostics
Complementing our research use only testing services, we are working on the development of diagnostic testing services from native patient samples and plan to eventually offer an IVD test kit for use by any laboratory worldwide.
2018 for clinical isolates
2021 (expected) for native patient samples
Currently in development
Currently in development
Always Up-to-Date
Informed by a global and continuously updated reference database (ARESdb) to reflect epidemiology of microbial infections and resistance evolution.
Universal
Designed to detect any pathogen and antibiotic resistance using a single, standardized test starting from any native patient sample.
Fast
Compatible with turn-around-times of less than 6 hours at launch and 1-2 hours mid- to long term.
Any Patient Sample
Universal DNA-Sequencing Assay
Cloud-Based Test Report
Informed Precision Therapy
less than 6 hoursResearch & Epidemiology
Our digital health platform allows for connected research & epidemiology solutions as well as tracking of emerging antibiotic resistance over time and space.
With our partner network, we conveniently offer epidemiology sequencing services and reporting starting from clinical isolates, as well as cloud-based data interpretation solutions starting from next-generation sequencing raw data.
Additionally, we are currently preparing the setup of the first European reference laboratory for next-generation sequencing molecular microbiology solutions in Vienna, Austria to offer most convenient and rapid sample-to-answer testing services by overnight shipping from major European hubs.
Similarly, we are planning to set up a reference lab channel in the U.S.
Pharma Services
AI guided Drug Development
Accelerated development of novel antibiotics and combination therapies based on rational drug design & companion diagnostics.
To accelerate discovery and development of novel antibiotics, we offer a comprehensive portfolio of data-driven services for antimicrobial drug discovery, clinical development, and product lifecycle management.
At Ares Genetics, we provide pharma services leveraging the entire OpGen Group solutions portfolio. Our services support data-driven target and lead prioritization, accelerate clinical trials, augment clinical data for regulatory submissions, as well as inform antimicrobial use for effective antibiotic stewardship post launch.
Accelerated Development
Rational drug design & lead prioritization.
Reduced Costs
Streamlined trials and fast-tracked drug development.
Increased Revenues
Improved product lifecycle management and optimal drug positioning.
Early Stage Development
Target and MoA Analysis
Customized in silico target characterization, epidemiology, and Mode of Action (MoA) analysis.
Lead Prioritization
In vitro high throughput resistance resting combined with customized in silico data analysis solutions to predict likelihood and mechanisms of resistance.
Biomarker Discovery
Identification, validation and epidemiological assessment of antibiotic drug specific biomarkers for clinical trials and companion diagnostics.
MDx Development
Advanced in silico tools combined with profound experience in molecular microbiology assay design for clinical trial and companion diagnostic use.
Clinical Development
Deep Pathogen Characterization
Deep profiling of pathogens using whole genome sequencing to enrich clinical trial data for regulatory submissions.
Optimized Enrollment
Customized and off-the-shelf multiplex PCR panels for pathogens and resistance markers enabling rapid and targeted clinical trial enrollment.
Life Cycle Management
Companion Diagnostics
Customized multiplex PCR panels for rapid diagnostics and informed treatment decisions.
Molecular Epidemiology
Post-market surveillance, resistance evolution monitoring and services.